NEW YORK – TruGenomix and BlueBee said today they have forged a strategic partnership in the area of biomarker discovery and development for post-traumatic stress disorder.
The companies noted that the global COVID-19 pandemic may create a mental health crisis including an uptick in PTSD cases, underscoring the importance of methods for early identification of the condition. Current survey-based methods can be subjective, creating a need for unbiased genomic and data-driven technologies, the partners said.